A final OS analysis following the death of 203 (77%) of the 265 patients in Study 19, after more than 5 years of follow-up, revealed a longer OS of BRCA -mutated patients receiving olaparib maintenance therapy, but the differences between groups did not reach statistical significance [ 30 ].
← all excerpts
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
1
—
—